Thiol/Disulphide Homeostasis and Albumin in Vertigo

Completed

• Conditions: Vertigo, Peripheral; Oxidative Stress; Vertigo, Central Origin; Diagnosis

• Registration Number: NCT04070664
• Lead Sponsor: Ankara City Hospital Bilkent

Brief Summary

Vertigo is a common complaint in the Emergency Department (ED). The differential diagnosis of central and peripheral vertigo is a difficult issue that directly affects mortality. Magnetic resonance imaging (MRI) is the preferred diagnostic tool, but may not be suitable in all patients due to logistic and economic conditions. In this study, the investigators evaluated the role of thiol/disulfide homeostasis (TDH) parameters and ischemia modified albumin (IMA) levels to assist in the value of being used instead of MRI.

Detailed Description

The study was conducted in the ED using a prospective, non-randomized method, and included patients with complaints of acute onset vertigo over 18 years of age and who underwent brain MRI. Pregnant women, smokers, and those with significant neurological signs were excluded. Patients with acute ischemia with MRI were included in the central vertigo group, and patients with normal MRI were included in the peripheral vertigo group. Blood samples for native thiol (NT), total thiol (TT), disulfide, and IMA were collected from all patients at admission. Statistical analyzes were performed with IBM SPSS Statistics for Windows 16.0 Package Program.

Study Timeline

• Study Start: 2018-07-01
• Primary Completion: 2018-12-31
• Study Completion: 2018-12-31
• Status Verified: 2019-08
• Study First Submitted: 2019-08-22
• Study First Submitted QC: 2019-08-24
• Last Update Submitted: 2019-08-24
• Study First Posted: 2019-08-28
• Last Update Posted: 2019-08-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

• Patients with complaint of vertigo
• Patients over18 years of age

Exclusion Criteria

• Patients contraindicated for MRI due to metal prosthesis or claustrophobia
• Patients under 18 years of age
• Pregnant patients
• Tobacco users
• Patients exhibiting significant neurological signs or symptoms such as motor or sensory neurologic deficit, speech disorders, unconsciousness, or seizure
• Patients found to have any type of lesion such as a hematoma, mass, cyst, aneurysm, arteriovenous malformation, etc. other than ischemic infarcts on MRI
• Patients with an ischemic lesion other than posterior fossa lesions
• Patients with any type of infection, including upper respiratory tract and ear infections
• Patients previously diagnosed with peripheral vertigo
• Patients where the cause of lightheadedness was blood pressure disorders, cardiac ischemic and arrhythmic disorders, thromboembolic diseases, metabolic disorders, trauma, etc. rather than central and peripheral vertigo.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oxidative stress	6 months	Thiol/disulphide homeostasis
Ischemic status	6 months	Ischemia modified albumin

Trial Locations

Locations (1)

Ankara Yıldırım Beyazıt University, School of Medicine, Department of Emergency Medicine; 🇹🇷 Ankara, Çankaya, Turkey